March 26, 2018 / 12:17 PM / 7 months ago

BRIEF-Palatin Technologies Announces Submission Of Bremelanotide NDA To FDA

March 26 (Reuters) - Palatin Technologies Inc:

* PALATIN TECHNOLOGIES ANNOUNCES SUBMISSION OF BREMELANOTIDE NDA TO FDA FOR TREATMENT OF HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) IN PREMENOPAUSAL WOMEN Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below